A detailed history of Susquehanna International Group, LLP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 518,958 shares of ESPR stock, worth $835,522. This represents 0.0% of its overall portfolio holdings.

Number of Shares
518,958
Previous 2,045,769 74.63%
Holding current value
$835,522
Previous $5.48 Million 78.99%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$1.84 - $3.24 $2.81 Million - $4.95 Million
-1,526,811 Reduced 74.63%
518,958 $1.15 Million
Q1 2024

May 07, 2024

BUY
$2.02 - $3.02 $1.32 Million - $1.98 Million
655,495 Added 47.15%
2,045,769 $5.48 Million
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $578,476 - $2.44 Million
792,434 Added 132.55%
1,390,274 $4.16 Million
Q3 2023

Nov 14, 2023

SELL
$0.96 - $1.79 $43,422 - $80,965
-45,232 Reduced 7.03%
597,840 $585,000
Q2 2023

Aug 11, 2023

BUY
$1.2 - $1.76 $402,073 - $589,707
335,061 Added 108.78%
643,072 $893,000
Q1 2023

May 16, 2023

BUY
$1.46 - $7.3 $220,132 - $1.1 Million
150,776 Added 95.89%
308,011 $489,000
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $673,834 - $1.13 Million
132,384 Added 532.71%
157,235 $979,000
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $135,437 - $202,038
24,851 New
24,851 $167,000
Q1 2022

May 16, 2022

BUY
$3.34 - $5.56 $185,500 - $308,796
55,539 Added 133.52%
97,136 $451,000
Q3 2021

Nov 15, 2021

SELL
$11.34 - $21.37 $1.79 Million - $3.38 Million
-158,249 Reduced 79.19%
41,597 $501,000
Q2 2021

Aug 11, 2021

BUY
$19.4 - $28.71 $437,081 - $646,836
22,530 Added 12.71%
199,846 $4.23 Million
Q1 2021

May 17, 2021

BUY
$25.12 - $36.89 $3.24 Million - $4.76 Million
129,040 Added 267.3%
177,316 $4.97 Million
Q4 2020

Feb 16, 2021

BUY
$24.2 - $35.76 $730,622 - $1.08 Million
30,191 Added 166.94%
48,276 $1.26 Million
Q3 2020

Nov 16, 2020

SELL
$31.18 - $52.71 $3.68 Million - $6.23 Million
-118,154 Reduced 86.73%
18,085 $672,000
Q2 2020

Aug 14, 2020

SELL
$30.04 - $51.31 $1.58 Million - $2.7 Million
-52,690 Reduced 27.89%
136,239 $6.99 Million
Q1 2020

May 15, 2020

BUY
$27.44 - $73.84 $1.76 Million - $4.73 Million
64,091 Added 51.34%
188,929 $5.96 Million
Q4 2019

Feb 14, 2020

BUY
$35.4 - $59.82 $960,012 - $1.62 Million
27,119 Added 27.75%
124,838 $7.44 Million
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $1.46 Million - $2.01 Million
-42,265 Reduced 30.19%
97,719 $3.58 Million
Q2 2019

Aug 16, 2019

BUY
$40.1 - $52.33 $494,994 - $645,961
12,344 Added 9.67%
139,984 $6.51 Million
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $745,699 - $973,128
18,596 Added 17.05%
127,640 $5.94 Million
Q1 2019

May 15, 2019

SELL
$40.11 - $53.57 $3.57 Million - $4.77 Million
-88,956 Reduced 44.93%
109,044 $4.38 Million
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $2.97 Million - $6.27 Million
82,121 Added 70.87%
198,000 $7.76 Million
Q4 2017

Feb 14, 2018

BUY
$43.47 - $67.43 $5.04 Million - $7.81 Million
115,879
115,879 $7.63 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $107M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.